Articles tagged "Kidney transplantation"

2022 American Transplant Congress
Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series
B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹
¹Nephrology, University of Washington, Seattle, WA, ²Surgery, University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA
*Purpose: The optimal treatment for chronic active antibody-mediated rejection (ca-AMR) remains unclear. Tocilizumab (TCZ), a monoclonal antibody against IL-6, has been proposed in ca-AMR treatment…
2022 American Transplant Congress
Circulating Plasma Proteomics Analysis of CMV Infection in Kidney Transplantation
T. Sigdel¹, P. Boada¹, D. Gjertson², M. Rossetti², B. Fatou³, H. Steen³, J. Schaenman², S. Bunnapradist², E. Reed², M. Sarwal¹
¹UCSF, San Francisco, CA, ²UCLA, Los Angeles, CA, ³Harvard Medical School, Boston, MA
*Purpose: Cytomegalovirus (CMV) infection is a threat to kidney transplantation. We studied circulating host proteome perturbations due to CMV infection in kidney transplantation as it…
2022 American Transplant Congress
Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group
H. Sharma, A. Odugoudar, B. Devkaran, A. Rao, A. El-Bakry, T. Gunawardhane, D. Ridgway, M. Howse, S. Mehra
Department of Transplant Surgery, Royal Liverpool University Hospital, Liverpool, United Kingdom
*Purpose: The present study investigated the short-term biopsy-proven acute rejection rates and viral infection rates amongst our protocol of single-dose Alemtuzemab (Cohort 1) versus double…
2022 American Transplant Congress
Natural Antibodies Are Associated With Rejection And Long-term Renal Allograft Loss In A Multi-center International Cohort
S. B. See¹, X. Yang², C. Burger³, B. Lamarthée⁴, R. Snanoudj⁵, R. Shihab¹, D. S. Tsapepas⁶, P. Roy¹, S. Larivière-Beaudoin⁷, K. Hamelin⁷, A. Mendoza Rojas⁸, N. M. van Besouw⁸, A. Bartosic⁹, N. Daniel⁹, E. R. Vasilescu¹⁰, S. Mohan¹¹, D. Cohen¹¹, L. Ratner¹¹, C. C. Baan⁸, J. S. Bromberg⁹, H. Cardinal⁷, D. Anglicheau³, Y. Sun², E. Zorn¹
¹CCTI, Columbia University Irving Medical Center, New York, NY, ²Biostatistics, Columbia University Irving Medical Center, New York, NY, ³Necker Hospital, Paris, France, ⁴Necker-Enfants Malades Institute, Paris, France, ⁵Bicêtre Hospital, Paris, France, ⁶Surgery, Columbia University Irving Medical Center, New York, NY, ⁷CHUM, Montreal, QC, Canada, ⁸Erasmus MC, Rotterdam, Netherlands, ⁹Surgery, University of Maryland School of Medicine, Baltimore, MD, ¹⁰Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, ¹¹Medicine, Columbia University Irving Medical Center, New York, NY
*Purpose: Potentially harmful non-donor-specific human leukocyte antigen antibodies have been identified in renal transplantation, including natural IgG antibodies (Nabs) reactive to varied antigenic structures.*Methods: In…
2022 American Transplant Congress
Regulatory T Cell PopulationsMay be Associated with Transplant Outcomes
H. Shin, S. Heo, Y. Kim, N. Lee, Y. Kim, Y. Jung, H. Rim
Internal Medicine, Kosin University College of Medicine,Transplantation Research Institute,Gospel Hospital, Busan, Korea, Republic of
*Purpose: The development of immunosuppressants has enabled remarkable progress in kidney transplantation (KT). However, current immunosuppressants cannot achieve induction of immune tolerance and their nonspecific…
2022 American Transplant Congress
Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens
H. Hames¹, A. R. Shields¹, E. Yanqui¹, A. Christianson¹, J. Kremer², A. Govil¹, E. S. Woodle¹, R. R. Alloway¹
¹University of Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: A prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based, calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a tacrolimus (TAC)-based ESW…
2022 American Transplant Congress
Local Cognate Antigen in Kidney Allografts Promotes Tissue Resident Memory T Cell Maintenance
R. Tieu¹, Q. Zeng¹, D. Zhao¹, P. Manandhar², A. Williams¹, K. Abou-Daya¹, L. Kane², W. Shlomchik¹, M. Oberbarnscheidt¹, F. Lakkis¹
¹Starzl Transplantation Institute, Pittsburgh, PA, ²Department of Immunology, University of Pittsburgh, Pittsburgh, PA
*Purpose: Our lab has demonstrated that tissue resident memory T cells (TRM cells) sustain chronic kidney allograft rejection in mice. It remains unknown how TRM…
2022 American Transplant Congress
No Grapefruit Juice Interaction with Tacrolimus LCP in Kidney Transplant Recipients
J. Kerr¹, Y. Sepulveda², M. Shah³, A. Khan⁴, J. D. Momper², S. Tsunoda²
¹Center for Transplantation, UC San Diego Health, San Diego, CA, ²UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, ³Nephrology, UC San Diego Health, San Diego, CA, ⁴UCSD Center for Transplantation, San Diego, CA
*Purpose: It is well known that grapefruit juice (GFJ) interacts with many medications through an intestinal CYP3A-mediated interaction that does not involve hepatic CYP3A and…
2022 American Transplant Congress
Enhanced Histological Yield and Actionable Findings When Biopsy is Guided by Donor-Derived Cell-Free DNA (dd-cfDNA)
M. R. Weir¹, D. Mandelbrot², J. S. Bromberg¹, S. Mehta³, E. Poggio⁴, E. Huang⁵, G. Shekhtman⁶, N. Agrawal⁷, W. Tian⁸, M. Cooper⁹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Wisconsin, Madison, WI, ³University of Alabama, Birmingham, AL, ⁴Cleveland Clinic, Cleveland, OH, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶CareDx Inc., Brisbane, CA, ⁷CareDx Inc, Brisbane, CA, ⁸CareDx, Brisbane, CA, ⁹MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: Implementation of molecular biomarkers in kidney transplantation has expanded the amount of information available to clinicians before deciding to pursue biopsy. We evaluated how…
2022 American Transplant Congress
A Pilot Study Using Registry-Based External Controls for the Cyclosporine Arm of the BENEFIT Study
A. Klein¹, D. Stewart², A. Toll², W. E. Fitzsimmons¹
¹Transplant Therapeutics Consortium, Critical Path Institute, Tucson, AZ, ²UNOS, Richmond, VA
*Purpose: The Transplant Therapeutics Consortium established a real-world evidence workgroup evaluating the potential of supplementing internal control arms with external controls to understand the impact…